Less Ads, More Data, More Tools Register for FREE

Pin to quick picksHikma Pharmaceuticals Share News (HIK)

Share Price Information for Hikma Pharmaceuticals (HIK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,930.00
Bid: 1,933.00
Ask: 1,935.00
Change: 17.00 (0.89%)
Spread: 2.00 (0.103%)
Open: 1,922.00
High: 1,936.00
Low: 1,904.00
Prev. Close: 1,913.00
HIK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Wednesday preview: WA votes in Parliament, Hikma Pharmaceuticals

Tue, 12th Mar 2019 14:55

(Sharecast News) - Investors may be facing heightened volatility on Wednesday, as financial markets digest the result of Parliament's vote on Theresa May's proposal for the UK's withdrawal agreement with the European Union.Going into the vote, some analysts were putting the odds of a vote in her favour at roughly 10%, which would trigger a vote on a no-deal exit on Wednesday and if the result of that was negative, then a third vote on Thursday on asking Brussels for a short on extension on Article 50.Hence, heightened uncertainty remained, among other reasons because the EU might impose conditions on any extension.As well, there was the possibility of various wildcards to contend with, including May's resignation or a no-confidence vote.Against that backdrop, the Chancellor was to deliver his Spring Statement, although the markets' focus may well turn out to be on the OBR's forecasts for economic growth over the next fiscal year, which might limit Philip Hammond's to dole out largesse.On the corporate side of things, Hikma Pharmaceuticals is among the companies slated to release full-year results.Consensus has penciled-in earnings per share of $1.29 versus $1.05 the last time around on a 6.7% increase in sales to $2.07bn, likely helped by better-than-expected sales of injectables Stateside and higher revenues from its generics arm.But supply disruptions, especially in opioids, meant that management was likely to offer "cautious" guidance on US injectables heading into fiscal year 2019, which might trigger consensus downgrades, Numis analyst Paul Cordon said."We also note the weak recent Q4 performance from Teva and Mylan, which may affect the generics outlook into FY19," he added."We would not expect any further update on the generic Advair program at this point with the trial nearing completion and due to be submitted to the FDA around the middle of the yearWednesday March 13INTERNATIONAL ECONOMIC ANNOUNCEMENTSCrude Oil Inventories (US) (14:30)Industrial Production (EU) (10:00)MBA Mortgage Applications (US) (11:00)Producer Price Index (US) (12:30)Q4Transgloble Energy Corporation NPV (DI)FINALSAdvanced Medical Solutions Group, Avast, Balfour Beatty, Burford Capital , Dignity, ECSC Group, EKF Diagnostics Holdings , Empresaria Group, Gem Diamonds Ltd. (DI), Hikma Pharmaceuticals, Kenmare Resources, Lookers, Manx Telecom , Marshall Motor Holdings, Morrison (Wm) Supermarkets, Prudential, Quilter, SafeCharge International Group Limited (DI), Sigmaroc , Standard Life Aberdeen, StatPro Group, Transgloble Energy Corporation NPV (DI)AGMSIndependent Inv Trust
More News
10 Nov 2020 13:17

Tuesday broker round-up

(Sharecast News) - On the Beach: Citigroup downgrades to neutral with a target price of 370p.

Read more
10 Nov 2020 09:44

UK BROKER RATINGS SUMMARY: Investec Cuts Barclays; Goldman Raises Next

UK BROKER RATINGS SUMMARY: Investec Cuts Barclays; Goldman Raises Next

Read more
5 Nov 2020 10:44

TOP NEWS: Hikma Lifts Annual Guidance; Launches Generic Drug In US

TOP NEWS: Hikma Lifts Annual Guidance; Launches Generic Drug In US

Read more
5 Nov 2020 09:24

LONDON MARKET OPEN: Pound Keeps Lid On FTSE 100 As BoE Boosts Support

LONDON MARKET OPEN: Pound Keeps Lid On FTSE 100 As BoE Boosts Support

Read more
5 Nov 2020 09:15

Hikma raises FY guidance for generics unit following positive H1 momentum

(Sharecast News) - Pharmaceutical company Hikma said on Thursday that the group as a whole was "performing well" and had maintained the positive momentum seen in the first half, leading it to reiterate guidance for one unit and raise it on another.

Read more
4 Nov 2020 17:06

LONDON MARKET CLOSE: Strong End To Choppy Session On Tight US Poll

LONDON MARKET CLOSE: Strong End To Choppy Session On Tight US Poll

Read more
4 Nov 2020 12:12

LONDON MARKET MIDDAY: Stocks In Europe Shake Off US Poll Uncertainty

LONDON MARKET MIDDAY: Stocks In Europe Shake Off US Poll Uncertainty

Read more
4 Nov 2020 10:38

UK WINNERS & LOSERS SUMMARY: Pharmaceutical Firms Rally

UK WINNERS & LOSERS SUMMARY: Pharmaceutical Firms Rally

Read more
29 Oct 2020 16:02

UK Earnings, Trading Statements Calendar - Next 7 Days

UK Earnings, Trading Statements Calendar - Next 7 Days

Read more
20 Oct 2020 11:03

Hikma Pharmaceuticals Expands US Collaboration With Arecor

Hikma Pharmaceuticals Expands US Collaboration With Arecor

Read more
1 Oct 2020 09:42

UK BROKER RATINGS SUMMARY: Goldman Raises Coca-Cola HBC And Cuts DCC

UK BROKER RATINGS SUMMARY: Goldman Raises Coca-Cola HBC And Cuts DCC

Read more
22 Sep 2020 19:34

IN BRIEF: Vectura Notes Hikma's Advair US Regulatory Setback

IN BRIEF: Vectura Notes Hikma's Advair US Regulatory Setback

Read more
22 Sep 2020 17:04

LONDON MARKET CLOSE: Stocks Rebound Slightly As Covid-19 Fears Remain

LONDON MARKET CLOSE: Stocks Rebound Slightly As Covid-19 Fears Remain

Read more
22 Sep 2020 10:37

UK WINNERS & LOSERS SUMMARY: Beazley's Virus Claims Estimate Doubles

UK WINNERS & LOSERS SUMMARY: Beazley's Virus Claims Estimate Doubles

Read more
22 Sep 2020 08:48

Hikma Expects To Gain FDA Approval For Advair Diskus In Early 2021

Hikma Expects To Gain FDA Approval For Advair Diskus In Early 2021

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.